These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31262041)

  • 1. Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
    Acheampong E; Spencer I; Lin W; Ziman M; Millward M; Gray E
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31262041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
    Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
    Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
    Kloten V; Lampignano R; Krahn T; Schlange T
    Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
    Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
    Dhar M; Wong J; Che J; Matsumoto M; Grogan T; Elashoff D; Garon EB; Goldman JW; Sollier Christen E; Di Carlo D; Kulkarni RP
    Sci Rep; 2018 Feb; 8(1):2592. PubMed ID: 29416054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system
    Raimondi C; Carpino G; Nicolazzo C; Gradilone A; Gianni W; Gelibter A; Gaudio E; Cortesi E; Gazzaniga P
    Oncoimmunology; 2017; 6(12):e1315488. PubMed ID: 29209560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1
    Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
    Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
    Janning M; Kobus F; Babayan A; Wikman H; Velthaus JL; Bergmann S; Schatz S; Falk M; Berger LA; Böttcher LM; Päsler S; Gorges TM; O'Flaherty L; Hille C; Joosse SA; Simon R; Tiemann M; Bokemeyer C; Reck M; Riethdorf S; Pantel K; Loges S
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.
    Acheampong E; Abed A; Morici M; Spencer I; Beasley AB; Bowyer S; Asante DB; Lomma C; Lin W; Millward M; Gray ES
    Transl Lung Cancer Res; 2022 Mar; 11(3):440-451. PubMed ID: 35399573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
    Dempke WCM; Fenchel K; Dale SP
    Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S275-S279. PubMed ID: 30393621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
    Ilie M; Hofman V; Dietel M; Soria JC; Hofman P
    Virchows Arch; 2016 May; 468(5):511-25. PubMed ID: 26915032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
    Cheng Y; Wang T; Lv X; Li R; Yuan L; Shen J; Li Y; Yan T; Liu B; Wang L
    Cancer Manag Res; 2020; 12():2069-2078. PubMed ID: 32256114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.